Pfizer Inc. (NYSE:PFE) shares are up during Thursday’s trading session after the company shared data from Talzenna plus Xtandi’s investigational treatment regimen for HRR gene-mutated metastatic castration-sensitive prostate cancer (mCSPC).

Pfizer Talzenna Plus Xtandi Hit Primary Goal

On Thursday, the U.S. drug giant reported topline data from the TALAPRO-3 Phase 3 study of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for metastatic hormone-sensitive prostate cancer.

The study met its primary endpoint, with Talzenna plus Xtandi demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS), compared to placebo plus Xtandi.

The results markedly exceeded the prespecified target hazard ratio of 0.63, with the majority of patients remaining progression-free at the time of ...